The active ingredient in Ozempic and Wegovy may help reduce the risk of kidney failure in those with Type 2 diabetes and chronic kidney disease, according to a study published in the New England Journal of Medicine. Researchers across 28 countries randomly assigned patients with Type 2 diabetes and chronic kidney disease to receive a weekly injection of 1 milligram of semaglutide, the active ingredient in Ozempic, or a placebo. Roughly 3,500 patients participated in the study, with half receiving semaglutide and the other half a placebo. The study, which began in 2019, was funded by Novo Nordisk, which manufactures semaglutide. In follow-ups among participants, the risk of a kidn
Hence then, the article about weight loss drugs reduce kidney complication risks study was published today ( ) and is available onThe Hill ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Weight-loss drugs reduce kidney complication risks: Study )